Ekso Bionics (NASDAQ:EKSO) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Sunday. The firm set a “hold” rating on the stock.

A number of other equities research analysts have also commented on the stock. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Ekso Bionics in a report on Tuesday, January 14th. Lake Street Capital decreased their price objective on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, October 29th.

Ekso Bionics Trading Down 2.6 %

NASDAQ:EKSO opened at $0.55 on Friday. The company has a fifty day moving average of $0.63 and a 200 day moving average of $0.84. Ekso Bionics has a 52 week low of $0.47 and a 52 week high of $2.16. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $12.01 million, a P/E ratio of -0.84 and a beta of 1.46.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.